KG
RXRX icon

Kieckhefer Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Kieckhefer Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Hold
74,000
– – 0.11% 58
2026
Q1 		$227K Hold
74,000
– – 0.11% 53
2025
Q4 		$303K Hold
74,000
– – 0.14% 41
2025
Q3 		$361K Buy
74,000
+36,000
+95% +$189K 0.17% 38
2025
Q2 		$192K Buy
+38,000
New +$187K 0.1% 44

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kieckhefer Group's RXRX Position: Q2 2026 in Review

Kieckhefer Group held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 74,000 shares worth $272K. The position accounts for 0.11% of the portfolio, ranked #58.

Kieckhefer Group first reported a position in RXRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $361K in Q3 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Kieckhefer Group held 74,000 shares of Recursion Pharmaceuticals worth $272K as of Q2 2026.
  • Kieckhefer Group left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up 0.11% of Kieckhefer Group's portfolio in Q2 2026, its #58 holding.
  • Kieckhefer Group first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Kieckhefer Group's Recursion Pharmaceuticals position peaked at $361K in Q3 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Kieckhefer Group's 13F filing for Q2 2026, filed 21 Jul 2026.